Neogenomics (NEO) Common Equity (2010 - 2026)

Neogenomics (NEO) has reported Common Equity for 17 consecutive years, with $785.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 8.0% year-over-year to $785.7 million; the trailing twelve-month figure through Jun 2026 stood at $785.7 million (down 8.0% YoY), and the FY2025 full-year result was $836.6 million, down 7.29% from the prior year.
• Common Equity fell to $785.7 million in Q2 2026 per NEO's latest filing, from $828.8 million in the prior quarter.
• Across five years, Common Equity topped out at $1.1 billion in Q1 2022 and bottomed at $785.7 million in Q2 2026.
• Historically, Common Equity has averaged $923.9 million across 5 years, with a median of $919.6 million in 2024.
• The widest YoY moves for Common Equity: up 27.41% in 2022, down 10.93% in 2022.
• Over 5 years, Common Equity stood at $998.0 million in 2022, then dropped by 5.66% to $941.5 million in 2023, then retreated by 4.16% to $902.3 million in 2024, then fell by 7.29% to $836.6 million in 2025, then fell by 6.08% to $785.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $785.7 million, $828.8 million, and $836.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.